Abstract Introduction Phosphodiesterase type 5 (PDE-5) hydrolyzes cyclic guanylate
monophosphate (cGMP) specifically to 5′ GMP, promoting successful corporeal vascular …

Abstract Introduction Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate
monophosphate specifically to 5′ guanylate monophosphate, promoting corporeal …

ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate
monophosphate (cGMP) specifically to 5′ GMP. PDE5 inhibitors were a breakthrough …

ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-
line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an …

Introduction: Erectile dysfunction (ED) is a highly prevalent condition affecting nearly one in
five men worldwide. The advent of phosphodiesterase type 5 inhibitors (PDE5i) has …

Aims To review developments within the past 18 months on the utilization of PDE5I in
preclinical studies and clinical practice. The focus of this article is on updates on regular …

ABSTRACT Background Nowadays, Oral phosphodiesterase type 5 inhibitors (PDE5Is) are
widely used for the treatment of erectile dysfunction (ED). However, these drugs have …

The causes of male erectile dysfunction (ED) are quite variable and are now commonly
divided into etiologies such as ischemia, smooth muscle damage, or altered blood flow …

Introduction Despite widespread use of the International Index of Erectile Function (IIEF) in
erectile dysfunction (ED) research, there are no published criteria for classifying ED …

Abstract Background The phosphodiesterase-5 (PDE5) inhibitors that have been available
for nearly 20 years are highly effective in treating erectile dysfunction and have been …